Not long ago, having early data about how an experimental drug worked in humans was expected of biotechs considering IPOs. Dyne Therapeutics may not reach human testing until 2022, but, like many of its preclinical peers this year, the company is choosing to jump into public markets now while investor interest in the biotech sector is riding high.
In paperwork filed with securities regulators late Tuesday, Dyne set a preliminary $100 million target for its IPO. The company has applied for a Nasdaq listing under the stock symbol “DYN.”
Waltham, MA-based Dyne is developing treatments for rare, inherited muscle disorders. The... Read more »
UNDERWRITERS AND PARTNERS
Author: Frank Vinluan
Date : 2020-08-26T17:47:32.000Z